bmiMD vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

bmiMD beats MEDVi overall, scoring 8/10 vs 7.7/10. MEDVi is more affordable at $299/mo vs $319/mo. Choose bmiMD for budget-first users who want affordable glp-1 access. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side comparison of bmiMD and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

bmiMD

#9 of 48

8/10

Budget-friendly GLP-1 platform offering both medication types at one of the lowest price points in the market.

Visit bmiMD

MEDVi

#22 of 48

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	bmiMD	MEDVi
Our Score	8/10	7.7/10
Starting Price	$319/mo	$299/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Budget-first users who want affordable GLP-1 access	Users who want a low entry price with oral and injectable compounded options
Ranking	#9	#22

Pros & Cons Compared

bmiMD

Pros

+Same-day physician consults — one of the few platforms offering telehealth appointments the same day you apply
+80,000+ customer base with 4.9-star Trustpilot rating provides strong social proof of reliability
+100% money-back guarantee if your consultation determines you don't qualify for GLP-1 treatment
+HSA/FSA accepted for all programs

Cons

−Starting at $289/mo for semaglutide — significantly more expensive than competitors at $99-199/mo
−$29.99 shipping fee per order — most competitors include free shipping
−$50 non-refundable cancellation fee after intake approval — penalizes patients who change their mind

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Our Verdict

bmiMD edges out MEDVi with a score of 8/10 vs 7.7/10. If budget is your priority, MEDVi starts at $299/mo compared to bmiMD's $319/mo. Choose bmiMD if you want: budget-first users who want affordable glp-1 access. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither bmiMD nor MEDVi feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Eden Health GLP-1→Read our full Eden Health GLP-1 review